Pharmacyclics, Inc.  

(Public, NASDAQ:PCYC)   Watch this stock  
Find more results for PCYC
121.84
+1.15 (0.95%)
Dec 24 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 120.30 - 124.84
52 week 82.51 - 154.89
Open 120.72
Vol / Avg. 363,627.00/679,211.00
Mkt cap 9.20B
P/E 111.66
Div/yield     -
EPS 1.09
Shares 75.53M
Beta 0.73
Inst. own 76%
Nov 11, 2014
Pharmacyclics Inc at Credit Suisse Healthcare Conference
Nov 6, 2014
Pharmacyclics Inc at Nomura Biotechnology Conference
Nov 4, 2014
Q3 2014 Pharmacyclics Inc Earnings Call
Nov 4, 2014
Q3 2014 Pharmacyclics Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin 20.00% 25.76%
Operating margin 23.35% 37.64%
EBITD margin - 38.49%
Return on average assets 19.18% 11.92%
Return on average equity 24.19% 15.06%
Employees 484 -
CDP Score - -

Address

995 E ARQUES AVE
SUNNYVALE, CA 94085-4521
United States - Map
+1-408-7740330 (Phone)
+1-408-7740340 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Pharmacyclics, Inc. is a United States-based biopharmaceutical company engaged in developing and commercializing small-molecule drugs for the treatment of cancer and immune mediated diseases. The Company designs, develops and commercializes therapies intended to improve quality of life, increase duration of life and resolve unmet medical healthcare needs of the patients. The Company also identifies and controls product candidates based on scientific development and administrational expertise. On November 13, 2013, the United States Food and Drug Administration approved IMBRUVICATM under accelerated approval as a monotherapy for the treatment of patients with mantle cell lymphoma (MCL). On November 13, 2013, the Company launched, developed, and commercialized its first product, IMBRUVICATM in the United States. In addition to IMBRUVICATM, the Company has three other product candidates in clinical development and other preclinical molecules in lead optimization.

Officers and directors

Robert W. Duggan Chairman of the Board, Chief Executive Officer
Age: 69
Bio & Compensation  - Reuters
Manmeet Soni Chief Financial Officer, Executive Vice President - Finance, Chief Accounting Officer, Treasurer
Age: 36
Bio & Compensation  - Reuters
Mahkam Zanganeh DDS Chief Operating Officer
Age: 43
Bio & Compensation  - Reuters
Rainer M. Erdtmann Senior Vice President - Investor Relations and Administration
Age: 50
Bio & Compensation  - Reuters
Urte Gayko Ph.D. Senior Vice President - Regulatory
Age: 42
Bio & Compensation  - Reuters
Sumita Ray Chief Compliance Officer, Associate General Counsel - Healthcare Law
Bio & Compensation  - Reuters
Gregory W. Hemmi Ph.D. Vice President - Chemical Operations
Age: 47
Bio & Compensation  - Reuters
Darrin Beaupre MD, PhD. Vice President - Clinical Medicine and Early Development
Bio & Compensation  - Reuters
Betty Y. Chang Ph.D. Vice President - Research/Biology
Bio & Compensation  - Reuters
Fong Wang Clow Vice President - Biostatistics, Programming, and Data Management
Age: 55
Bio & Compensation  - Reuters